Journal of the neurological sciences · 2021
Early detection of cognitive decline in mild cognitive impairment and Alzheimer's disease with a novel eye tracking test.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tadokoro Koh, Yamashita Toru, Fukui Yusuke, Nomura Emi, Ohta Yasuyuki, Ueno Setsuko, Nishina Saya, Tsunoda Keiichiro, Wakutani Yosuke, Takao Yoshiki, Miyoshi Takahiro, Higashi Yasuto, Osakada Yosuke, Sasaki Ryo, Matsumoto Namiko, Kawahara Yuko, Omote Yoshio, Takemoto Mami, Hishikawa Nozomi, Morihara Ryuta, Abe Koji
Аннотация
Due to an increasing number of dementia patients, the development of a rapid and sensitive method for cognitive assessment is awaited. Here, we examined the usefulness of a novel and short (3 min) eye tracking device to evaluate the cognitive function of normal control (NC, n = 52), mild cognitive impairment (MCI, n = 52), and Alzheimer's disease (AD, n = 70) subjects. Eye tracking total score declined significantly in MCI (**p < 0.01 vs NC) and AD (**p < 0.01 vs NC, ##p < 0.01 vs MCI), and correlated well with the mini-mental state examination (MMSE) score (r = 0.57, *p < 0.05). Furthermore, the eye tracking test, especially memory and deductive reasoning tasks, effectively discriminated NC, MCI and AD. The present novel eye tracking test clearly discriminated cognitive functions among NC, MCI, and AD subjects, thereby providing an advantage for the early detection of MCI and AD in screening.